About this trial
This is a multicenter, open label, Phase 1/2 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 (larotrectinib) will be administered orally (PO) twice daily (BID), with the dose adjusted by body surface area.
Patient Profile
Paediatric neoplasm or CNS neoplasm
Where’s this trial being run?
Crumlin Children’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | LOXO TRK 15003 |
|---|---|
| Number: | 18-36 |
| Full Title: | A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors. |
| Principal Investigator: | Dr Cormac Owens |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | LOXO |
| Recruitment Started: |
Global: Dec 2015 Ireland: Oct 2018 |
| Global Recruitment Target: | 112 |
|---|---|
| Ireland Recruitment Target: | Not Available |